When we feed the body correctly, we can influence the same systems that drugs like Mounjaro target - helping regulate ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

Why is an increase of nearly 48% in India’s coastline relevant to the UPSC exam? What is the significance of topics such as ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of treatment Tirzepatide users experienced greater waistline reduction (7. ...

Dubbed the “King Kong” of weight loss jabs, Mounjaro, the brand name for tirzepatide, is a weekly injection licensed to treat type 2 diabetes on the NHS.

Tirzepatide is associated with longer continuous glycemic control than placebo or active comparators in type 2 diabetes (T2D). These findings, from a post hoc analysis, were published in Diabetes ...

Tirzepatide was also related with decreased risk for all-cause hospitalization at 1 year (OR, 0.312; 95% CI, 0.279-0.349).

Compounded tirzepatide is not approved by the FDA. This means the FDA does not regulate the safety, quality, or effectiveness of the drug. Instead, each state regulates its compounding pharmacies.

Under the brand name Wegovy (Novo Nordisk), semaglutide was approved for chronic weight management in 2021, 2 and as Zepbound (Eli Lilly), tirzepatide was approved for the same indication in 2023 ...